VBI Vaccines

120 articles with VBI Vaccines

• VBI Vaccines to Participate in Jefferies London Healthcare Conference

  11/16/2021

  VBI Vaccines Inc. today announced that Jeff Baxter, President and CEO, will participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17 at 12:20 PM GMT / 7:20 AM ET.

• VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update

  11/8/2021

  VBI Vaccines Inc. today reported financial results for the third quarter ending September 30, 2021 and provided a corporate update.

• VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021

  11/1/2021

  VBI Vaccines Inc. today announced that its abstract highlighting data from PROTECT, the pivotal Phase 3 immunogenicity and safety study of its 3-antigen prophylactic hepatitis B (HBV) vaccine, was accepted for e-poster presentation at the American Association for the Study of Liver Disease

• VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open

  10/13/2021

  VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open.

• VBI Vaccines to Participate in Upcoming Investor Conferences - Oct 04, 2021

  10/4/2021

  VBI Vaccines Inc., a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, announced that members of the management team will participate in analyst-led fireside chats at the following upcoming investor conferences.

• VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern

  9/29/2021

  VBI Vaccines Inc. today announced positive results from multiple preclinical studies against several COVID-19 variants of concern as well as the initiation of dosing in the Phase 1b portion of the ongoing clinical study of VBI’s SARS-CoV-2 vaccine candidates in approximately 80 adults age 18-54.

• VBI Vaccines Appoints Linda Bain to Board of Directors

  7/7/2021

  VBI Vaccines Inc. today announced that Linda Bain, Chief Financial Officer of Codiak BioSciences, Inc., has joined its Board of Directors.

• VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine

  7/1/2021

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Panel has established a unique CPT code for a 3-antigen (S, Pre-S1, Pre-S2) Hepatitis B (HBV) vaccine.

• VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19

  6/29/2021

  The Phase 1 portion of the ongoing Phase 1/2 study evaluated one- and two-dose regimens of 5µg of eVLP candidate, VBI-2902a, in 61 healthy adults age 18-54 years

• Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021

  6/23/2021

  Brii Biosciences today announced final results from a Phase 1b/2a study on BRII-179 (VBI-2601), a novel recombinant, protein-based immunotherapeutic candidate, in patients with chronic hepatitis B virus (HBV) infection.

• VBI Vaccines to Present at Upcoming Scientific Conferences - June 17, 2021

  6/17/2021

  VBI Vaccines Inc. announced that two abstracts featuring data from the Phase 3 clinical program of the Company’s prophylactic 3-antigen hepatitis B vaccine candidate have been accepted for upcoming e-poster presentations at the Global Hepatitis Summit 2020/2021 and the American Diabetes Association’s Virtual 81st Scientific Sessions.

• VBI Vaccines Announces Results of Annual General Meeting - June 09, 2021

  6/9/2021

  VBI Vaccines Inc., a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, announced the voting results from its annual general meeting of shareholders held on June 9, 2021.

• VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021

  6/9/2021

  VBI Vaccines Inc. today announced that two abstracts featuring data from the Company’s prophylactic and therapeutic hepatitis B (HBV) candidates have been accepted for presentation at The Digital International Liver Congress™ 2021.

• VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM

  6/8/2021

  FDA’s Fast Track Designation for VBI-1901 underscores the significant and urgent unmet medical need for new therapies for recurrent glioblastoma (GBM) patients.

• VBI Vaccines to Participate in Upcoming Investor Conferences

  6/1/2021

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, President and Chief Executive Officer, and David E. Anderson, Ph.D., Chief Scientific Officer, will participate in analyst-led fireside chats at the following upcoming investor conferences:

• VBI Vaccines Announces $12 Million Second Tranche of Debt Financing with K2 HealthVentures

  5/21/2021

  VBI Vaccines Inc. ( Nasdaq: VBIV ) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced an agreement to drawdown a $12 million second tranche under its previously announced debt financing facility with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company. Under the terms of the debt financing facility, dated May 22, 2021

• VBI Vaccines to Present Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting

  5/20/2021

  - 12-month overall survival (OS) : 60% (n=6/10) in VBI-1901 + GM-CSF study arm compared to historical controls of ~30% 1 –­ 12-month OS not yet reached with VBI-1901 + AS01 B 2 - 6-month OS : 80%+ survival achieved across both study arms compared to historical controls of ~60% 1 - 2 partial tumor responses and 7 stable disease observations across both study arms - Full data to be highlighted in ASCO poster presentation June 4-8, 2021

• VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases

  5/12/2021

  VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases

• VBI Vaccines Announces First Quarter 2021 Financial Results and Provides Corporate Update

  5/10/2021

  Hepatitis B : FDA and EMA regulatory review of VBI’s 3-antigen prophylactic HBV vaccine candidate ongoing – U.S. PDUFA target action date November 30, 2021 COVID-19 : Initial data from ongoing Phase 1/2 study of VBI-2902, VBI’s monovalent COVID-19 vaccine candidate, expected by end of Q2 2021

• VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021

  5/3/2021

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that two abstracts highlighting data from the pivotal Phase 3 program evaluating the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine candidate have been accepted for oral and poster presentation at the Canadian Liver Meeting 2021